Be Ready for the New Combo HIV Med Biktarvy

June 2018

Biktarvy (bik-TAR-vee, bictegravir/emtricitabine/tenofovir alafenamide) will be a new first-line option for HIV.

Think of it as a complete HIV regimen in one pill.

Biktarvy combines a new integrase inhibitor, bictegravir...with two nucleoSIDE/nucleoTIDE reverse transcriptase inhibitors (NRTIs), emtricitabine and tenofovir alafenamide.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Naloxone Streamline Processes for Providing Naloxone
Epinephrine Help Patients Get the Right Epinephrine Auto-Injector
Anticoagulants Lean Toward Eliquis for the Best Balance of Efficacy and Safety in Atrial Fib
Diabetes Don't Advise Routine Glucose Monitoring if Results Won't Be Used
Depression Stay Alert for Depression in Teens
OTC Products Shed Light on Lumify's Role in Relieving Red Eyes
Nebulizers Clarify Differences Between Lonhala Magnair and Other Nebulizers
Toxicology Expect Unusual Vitamin K Doses for Synthetic Cannabinoid Bleeding
Antithrombotics Think of Antiplatelets for Arterial Clots and Anticoagulants for Venous Clots
Asthma Watch for Tiotropium or Biologics for Severe Asthma
HIV & AIDS Be Ready for the New Combo HIV Med Biktarvy
Practice Use These Tips to Determine Whether Marketing Is Just Hype

Be Ready for the New Combo HIV Med Biktarvy

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents